Naples Global Advisors LLC Trims Stock Holdings in Sanofi $SNY

Naples Global Advisors LLC lowered its stake in shares of Sanofi (NASDAQ:SNY) by 3.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,337 shares of the company’s stock after selling 400 shares during the period. Naples Global Advisors LLC’s holdings in Sanofi were worth $548,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Accent Capital Management LLC purchased a new stake in shares of Sanofi during the first quarter worth about $29,000. Eastern Bank lifted its stake in shares of Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after buying an additional 300 shares during the period. Banque Transatlantique SA acquired a new stake in Sanofi during the first quarter worth approximately $33,000. Golden State Wealth Management LLC grew its stake in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock worth $35,000 after acquiring an additional 545 shares during the period. Finally, Brentview Investment Management LLC acquired a new position in Sanofi in the 1st quarter valued at $42,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on SNY shares. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Saturday, September 27th. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Finally, Barclays restated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Stock Performance

NASDAQ SNY opened at $50.90 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The firm has a market capitalization of $124.99 billion, a P/E ratio of 12.24, a P/E/G ratio of 1.19 and a beta of 0.51. The business’s 50-day simple moving average is $48.19 and its 200-day simple moving average is $50.09.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period last year, the company posted $1.73 EPS. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year. Equities analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.